See more : ITM Power Plc (ITM.L) Income Statement Analysis – Financial Results
Complete financial analysis of Arcadia Biosciences, Inc. (RKDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcadia Biosciences, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- Ozner Water International Holding Limited (2014.HK) Income Statement Analysis – Financial Results
- Namyong Terminal Public Company Limited (NYT.BK) Income Statement Analysis – Financial Results
- Panasonic Energy India Co. Ltd. (PANAENERG.BO) Income Statement Analysis – Financial Results
- Marico Limited (MARICO.NS) Income Statement Analysis – Financial Results
- Shell plc (RYDAF) Income Statement Analysis – Financial Results
Arcadia Biosciences, Inc. (RKDA)
About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.33M | 9.96M | 6.78M | 8.03M | 1.17M | 1.46M | 4.03M | 3.19M | 5.41M | 6.98M | 6.48M | 7.01M |
| Cost of Revenue | 3.30M | 9.80M | 8.71M | 5.20M | 885.00K | 661.00K | 283.00K | 895.00K | 892.00K | 2.00M | 673.00K | 909.00K |
| Gross Profit | 2.03M | 154.00K | -1.93M | 2.84M | 284.00K | 803.00K | 3.74M | 2.29M | 4.52M | 4.99M | 5.81M | 6.10M |
| Gross Profit Ratio | 38.09% | 1.55% | -28.44% | 35.29% | 24.29% | 54.85% | 92.97% | 71.93% | 83.52% | 71.40% | 89.61% | 87.03% |
| Research & Development | 1.39M | 1.51M | 3.89M | 7.96M | 7.10M | 6.07M | 7.41M | 8.66M | 8.97M | 10.01M | 8.40M | 7.95M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 16.47M | 13.57M | 11.60M | 10.65M | 12.25M | 11.12M | 10.13M | 7.97M | 8.28M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.51M | 18.05M | 22.94M | 16.47M | 13.57M | 11.60M | 10.65M | 12.25M | 11.12M | 10.13M | 7.97M | 8.28M |
| Other Expenses | 73.00K | 33.00K | 10.11M | 105.00K | 466.00K | -3.61M | 281.00K | 340.00K | 521.00K | 0.00 | 5.00K | 8.00K |
| Operating Expenses | 15.90M | 19.56M | 26.83M | 24.43M | 20.67M | 17.67M | 18.06M | 20.91M | 20.09M | 20.14M | 16.37M | 16.23M |
| Cost & Expenses | 19.27M | 29.36M | 35.54M | 29.63M | 21.55M | 18.33M | 18.34M | 21.81M | 20.98M | 22.14M | 17.04M | 17.14M |
| Interest Income | 695.00K | 289.00K | 20.00K | 47.00K | 5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 289.00K | 20.00K | 47.00K | 5.00K | 0.00 | 747.00K | 1.32M | 2.66M | 1.39M | 626.00K | 186.00K |
| Depreciation & Amortization | 287.00K | 1.36M | 1.04M | 662.00K | 194.00K | 154.00K | 279.00K | 304.00K | 294.00K | 358.00K | 391.00K | 378.00K |
| EBITDA | -13.58M | -13.65M | -23.27M | -5.44M | -28.67M | -13.32M | -14.66M | -17.98M | -14.98M | -15.39M | -10.17M | -9.74M |
| EBITDA Ratio | -254.75% | -228.21% | -270.87% | -259.21% | -1,747.56% | -1,562.64% | -341.65% | -563.86% | -272.40% | -211.90% | -156.99% | -139.00% |
| Operating Income | -13.94M | -19.40M | -35.53M | -21.59M | -20.38M | -16.87M | -14.32M | -18.62M | -15.56M | -15.15M | -10.57M | -10.13M |
| Operating Income Ratio | -261.50% | -194.89% | -523.98% | -268.76% | -1,743.46% | -1,152.32% | -355.56% | -584.07% | -287.46% | -217.03% | -163.11% | -144.51% |
| Total Other Income/Expenses | 781.00K | 3.19M | 19.39M | 6.63M | -9.49M | 3.40M | -1.37M | -979.00K | -2.37M | -1.99M | -621.00K | -178.00K |
| Income Before Tax | -13.16M | -15.60M | -16.13M | -6.15M | -28.87M | -13.47M | -15.68M | -19.60M | -17.93M | -17.14M | -11.19M | -10.31M |
| Income Before Tax Ratio | -246.85% | -156.67% | -237.94% | -76.55% | -2,469.72% | -920.08% | -389.49% | -614.77% | -331.18% | -245.55% | -172.69% | -147.05% |
| Income Tax Expense | 8.00K | 14.00K | 2.00K | -124.00K | 2.00K | 10.00K | 26.00K | 25.00K | 26.00K | 263.00K | 167.00K | 213.00K |
| Net Income | -13.98M | -15.61M | -16.13M | -6.03M | -28.87M | -13.48M | -15.71M | -19.62M | -17.96M | -18.34M | -13.20M | -12.37M |
| Net Income Ratio | -262.31% | -156.81% | -237.96% | -75.01% | -2,469.89% | -920.77% | -390.14% | -615.56% | -331.66% | -262.66% | -203.69% | -176.46% |
| EPS | -11.30 | -26.05 | -30.33 | -24.20 | -181.50 | -143.16 | -291.38 | -353.85 | -503.00 | -448.39 | -322.62 | -302.44 |
| EPS Diluted | -11.30 | -26.05 | -30.33 | -24.20 | -181.50 | -143.16 | -291.38 | -353.85 | -503.00 | -448.39 | -322.62 | -302.44 |
| Weighted Avg Shares Out | 1.24M | 599.39K | 532.02K | 248.98K | 159.08K | 94.16K | 53.91K | 55.46K | 35.70K | 40.90K | 40.90K | 40.90K |
| Weighted Avg Shares Out (Dil) | 1.24M | 599.39K | 532.02K | 248.98K | 159.08K | 94.16K | 53.91K | 55.46K | 35.70K | 40.90K | 40.90K | 40.90K |
4 Penny Stocks With Huge Potential According To Analyst Forecasts
4 Hot Penny Stocks To Buy According To Analysts. The post 4 Penny Stocks With Huge Potential According To Analyst Forecasts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Arcadia Biosciences (RKDA) Names Stan Jacot as CEO
DAVIS, Calif., Feb. 2, 2022 /PRNewswire/ -- Arcadia Biosciences, Inc. ® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, has appointed veteran consumer goods leader Stan Jacot as chief executive officer, effective today.
Arcadia Biosciences (RKDA) Appoints Kevin Comcowich to Interim CEO
DAVIS, Calif., Dec. 20, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc. ® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim...
Arcadia Biosciences (RKDA) Appoints Seasoned CPG Sales Executive Brian Schaffer to Senior Vice President of Sales
DAVIS, Calif., Nov. 22, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc. ® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has named Brian Schaffer as senior vice president of sales, as the company...
Arcadia Biosciences' (RKDA) CEO Matt Plavan on Q3 2021 Results - Earnings Call Transcript
Arcadia Biosciences' (RKDA) CEO Matt Plavan on Q3 2021 Results - Earnings Call Transcript
Arcadia Biosciences (RKDA) Announces Strong Third-Quarter Financial Results and Business Highlights
DAVIS, Calif., Nov. 15, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.
Arcadia Biosciences Earnings Preview
Arcadia Biosciences (NASDAQ:RKDA) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.
Arcadia Biosciences kicks off its search for a new CEO
Arcadia Biosciences, Inc said it has launched a national search for a new CEO as the company further expands into the consumer packaged goods (CPG) sector. Current CEO Matt Plavan will step down from the role once a successor is named,...
Arcadia Biosciences Announces Leadership Transition
DAVIS, Calif., Sept. 7, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that it has launched a national search for a new Chief Executive Officer as the company...
Arcadia Biosciences sees five-fold revenue growth in 2Q as it records first consumer brand sales
Arcadia Biosciences reported a five-fold increase in revenue in its second quarter, mainly thanks to sales from the newly acquired portfolio of wellness brands, as well as its GoodHemp seed sales. For the three months to June 30, the maker...
Source: https://incomestatements.info
Category: Stock Reports